Skip to content

Alumis Inc. ALMS Total Revenue

Total Revenue at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$11.49B+2.6%
Amgen logo
AmgenAMGN
$8.62B+5.8%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$15K-97.8%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$396K-81.8%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$56.37M+99.0%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$34.37M+55.5%

Segments

By segment

See full
Single Reportable$1.74M-90.0%

By product

See full
Collaboration Revenue$1.74M

Other financials

Income statement

See full
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.12B+739%
Enterprise value$3.1B+1,238%
P/S371.9×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s total revenue?
Alumis Inc. (ALMS) reported total revenue of $1.74M in Q1 2026.
How has Alumis Inc.'s total revenue changed year-over-year?
Alumis Inc.'s total revenue decreased by 90.0% year-over-year, from $17.39M to $1.74M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.